DaVita: Better Results Than Fresenius, But A 'Hold' Due To Valuation
Despite operational success and growth potential, I rate DaVita Inc. a “Hold” due to its high debt, lack of dividend, and current overvaluation. DaVita excels in dialysis services but faces significant risks from debt servicing costs, macroeconomic factors …